Vesugen

What Vesugen is, structurally

Vesugen is a tripeptide with a free N-terminal amine and a free C-terminal acid.

The formula reconciles exactly. Four nitrogens means three backbone amides plus the lysine's epsilon-amino group, neither acidic residue contributing one. The eight oxygens divide as two backbone carbonyls, two for the terminal acid, and four across the acidic side chains.

Arrangement matters more than composition here. Lysine sits at the N-terminus with two acidic side chains behind it, giving a net negative charge but a mixed distribution rather than a uniformly anionic one. That shows up in column behaviour and counter-ion, both covered below.

The aspartate occupies the C-terminal position, which has a specific consequence for stability set out under storage. It is the most important structural fact about this compound and easy to miss.

There is no cysteine, no methionine, no asparagine or glutamine, and no aromatic residue anywhere. The peptide is highly polar and freely water soluble, though no quantitative figure is quoted here.

Reconstitution and handling

Sterile water is the default solvent, and with no metal centre present PBS or an appropriate assay buffer are equally suitable. Add diluent down the vial wall, swirl gently, and let it stand until clear. A tripeptide of this polarity dissolves readily and vortexing serves no purpose.

pH warrants attention for a different reason than elsewhere in this family. With a basic lysine and two acidic side chains, net charge shifts appreciably across the mildly acidic range as the carboxylates titrate, so an unbuffered solution can drift in charge state while remaining chemically intact.

Adsorption onto plasticware is worth allowing for at low concentration, with low-protein-binding tubes reducing measured loss, though a small mixed-charge peptide has limited affinity for polypropylene.

This is laboratory preparation chemistry, not dosing, administration, or protocol guidance of any kind.

Storage and stability

Store the lyophilized powder at -20 degrees C, sealed, desiccated and protected from light, and let a cold vial warm before opening. Reconstituted, hold at 2 to 8 degrees C, or aliquot and freeze rather than thawing repeatedly.

The composition rules out most peptide degradation immediately. No cysteine means no thiol oxidation, no methionine means no sulfoxide, and no asparagine or glutamine means no deamidation.

That leaves the aspartate, and the aspartate turns out not to be a liability here either, for positional reasons. Aspartyl residues rearrange to isoaspartate through a succinimide ring, which forms when the backbone nitrogen of the residue following the aspartate attacks its side chain. In this sequence the aspartate is the C-terminal residue. There is no following residue, so there is no such nitrogen, and the rearrangement cannot occur at all.

This is worth stating explicitly, because composition alone suggests the opposite. An aspartate-containing sequence is normally assumed to carry the isoaspartate liability, correctly in most arrangements but not this one. The route is closed by where the residue sits, not slowed by what surrounds it.

What remains is ordinary amide hydrolysis under strongly acidic or alkaline conditions, slow near neutral pH. Cold, dry, near-neutral storage covers it, and this compound has no single vulnerable residue to protect.

How Vesugen is tested

Reversed-phase HPLC establishes chromatographic purity as area percent. With no aromatic residue there is no absorbance at 280 nm, so detection sits near 214 nm where the amide bond absorbs.

Retention is poor, as it is for any small highly charged peptide, and the mixed charge here complicates ion pairing rather than simplifying it. Trifluoroacetate pairs with the lysine, but the two carboxylates are unaffected by it, so the molecule is only partially neutralised by a standard ion-pairing additive and still elutes early.

Area percent is a chromatographic measure rather than peptide content by weight. Solid-phase synthesis delivers a salt, and on a 390 g/mol peptide with a single basic site the counter-ion is a substantial proportional share of the vial contents.

Mass spectrometry confirms identity against the expected weight, and the blind spot limiting most aspartate-containing peptides does not apply. Isoaspartate is isobaric and therefore invisible to mass, but since that rearrangement cannot occur here there is nothing invisible to miss. A deletion product is a large proportional change on a tripeptide and separates cleanly.

Handling FAQ

Does the aspartate make this prone to isoaspartate formation? No, and this is the exception rather than the rule. The rearrangement needs the backbone nitrogen of the following residue to attack the aspartate side chain. Here the aspartate is last in the sequence, so no following residue exists and the reaction has no route. Composition would suggest a liability that the arrangement removes.

Why does ion pairing work less well on this peptide? Because the charge is mixed. Trifluoroacetate neutralises the lysine but does nothing for the glutamate and aspartate carboxylates, so the molecule retains negative charge and remains poorly retained on a reversed-phase column despite the additive.

Full specifications for Vesugen.